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Abstract Contrary to common perception, modern palliative care (PC) is applicable to all people with an incurable disease, not
only cancer. PC is appropriate at every stage of disease progression, when PC needs emerge. These needs can be of
physical, emotional, social, or spiritual nature. This document encourages the use of validated assessment tools to rec-
ognize such needs and ascertain efficacy of management. PC interventions should be provided alongside cardiologic
management. Treating breathlessness is more effective, when cardiologic management is supported by PC interven-
tions. Treating other symptoms like pain or depression requires predominantly PC interventions. Advance Care
Planning aims to ensure that the future treatment and care the person receives is concordant with their personal values
and goals, even after losing decision-making capacity. It should include also disease specific aspects, such as modification
of implantable device activity at the end of life. The Whole Person Care concept describes the inseparability of the
physical, emotional, and spiritual dimensions of the human being. Addressing psychological and spiritual needs, together
with medical treatment, maintains personal integrity and promotes emotional healing. Most PC concerns can be
addressed by the usual care team, supported by a PC specialist if needed. During dying, the persons’ needs may change
dynamically and intensive PC is often required. Following the death of a person, bereavement services benefit loved
ones. The authors conclude that the inclusion of PC within the regular clinical framework for people with heart failure
results in a substantial improvement in quality of life as well as comfort and dignity whilst dying.
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1. Introduction
Heart failure (HF) affects about 1–2% of the general adult population in
high-income countries.1 At least 5% of this group suffers from symptoms
at minimal exercise or at rest [Class III or IV of HF according to New York
Heart Association (NYHA) classification] despite optimal cardiologic man-
agement.2–4 People with advanced HF have a risk of premature death
(80% of people with advanced HF die within 5 years) and report physical
symptoms, psychosocial burdens, and spiritual needs similar to those
reported by people with other advanced diseases, including cancer.5–7
Scientific societies representing palliative care (PC), including the
European Association for Palliative Care (EAPC), and cardiology, includ-
ing the European Society of Cardiology recommend PC for people
with advanced HF in order to improve their quality of life (QoL) and dy-
ing.1,8–14 QoL has hardly been considered as an endpoint in large multi-
centre randomized trials, and the added value of PC provided along with
optimal cardiological treatment has only been shown recently in one sin-
gle centre randomized study.15 Access to PC throughout the whole
course of HF, accordingly to needs, has been advocated.16 The World
Health Organisation has recently recognized access to PC for all people
who need it as an essential criterion of Universal Health Coverage.17
Although heart disease has been included in the 20 health conditions
most commonly resulting in either death or suffering severe enough to
require PC intervention,18 and circulatory disease is the leading cause of
death (34% of all deaths),19 only a minority of people with HF across
Europe receive PC20–22 (merely 7% HF decedents compared with 50%
of cancer patients had their PC needs recognized, and <1% of patients
dying in hospices have HF as the primary diagnosis),23 for a very short
time (the mean time from PC referral to death is <2 weeks; significantly
shorter than for people with cancer).24 Improving access to PC for peo-
ple with advanced HF might reduce their suffering and that of their loved
ones, as well as decrease hospital readmissions.15,25–29
The Board of the EAPC, recognizing the urgent need to improve the
provision of PC for people with HF, has endorsed the initiative of profes-
sionals providing such care and approved the Task Force on Palliative
Care for People with Heart Disease.30 A group of multi-professional
experts working in the field of PC and cardiology (physicians, nurses, eth-
icists, allied health professionals, and spiritual carers) from 10 countries
has been charged on behalf of the EAPC with evaluating the existing data
and current clinical practices with respect to PC for people living with
HF. This position statement presents agreed opinions of these experts
and has been approved by the EAPC Board for publication. The follow-
ing topics will be discussed: basic definitions, symptom assessment, trig-
gers for initiating PC, symptom management (breathlessness, pain,
depression, and anxiety), advance care planning, spirituality and whole
person care, addressing ethical dilemmas, adjustment of medical therapy,
care for dying, and PC services.
2. Basic definitions
A variety of terms meaningful for this article are used internationally with
varying interpretations. This, and a misperception amongst the lay public,
patients, their families, and non-PC clinicians, often leads to belief that
PC is only relevant to the last few weeks or days of life. This mispercep-
tion is a major barrier to access PC for people with heart disease. A main
aim of this article is to facilitate the correct understanding of the broad
nature and wide applicability of PC for people living with HF. For clarity,
key definitions for this document are therefore presented:
Palliative care is the active, total care for a person with incurable dis-
ease; that is, disease which may still respond to disease-modifying treat-
ments, but is nonetheless progressive and life-shortening.31 PC is neither
limited to a specific diagnosis, nor to a particular prognosis, and even if
decline trajectories and patient characteristics differ among specific dis-
ease, the principle of PC, focusing on the improvement of the QoL, is
universal. Ideally, PC should be introduced early on in the disease trajec-
tory and increased as the disease progresses1 or reduced/withdrawn if the
condition improves (Figure 1). PC addresses symptoms and social, psycho-
logical, and spiritual problems.31 It affirms life and regards dying as a normal
process; it aims to neither hasten nor postpone death. PC should be pro-
vided alongside optimal disease specific management and care.1,8,32
Hospice care is a specific form of PC service dedicated to the whole
person who approaches death and for those who love her/him. Care is
focused on the individual’s needs and personal choices, striving to offer
freedom from pain, dignity, peace, and calm. It is not primarily aimed at
saving life or finding a cure.33 In Europe, hospice care is often provided
by freestanding centres offering care in the patient’s home or in a home-
like in-patient setting. In the USA, a hospice is a specific insurance benefit
dedicated to people who forgo life-prolonging therapies. In several coun-
tries ‘hospice care’ is used interchangeably with ‘specialist PC’. This arti-
cle refers to a broad spectrum of PC.
End of life (EoL) is the period preceding a person’s natural death, char-
acterized by the progression of a disease, which cannot be arrested by
medical treatment. Depending on the person, her/his characteristics, the
underlying disease and comorbidities different durations of expected
survival are understood in the literature and policy in different countries
as EoL—from several months until the last few days of life. EoL should
be distinguished from active dying—a short period preceding imminent
death, characterized by the waning of the physiological functions of a
person and, limited to the last days or hours of life.34
Transition of care is a change in the place, level, or goals of care. The main
domains of care goals can be: cure, prolonging survival, optimizing function,
improving comfort, achieving life goals, and supporting the family/caregiver.
Transition of care is common and important during advanced disease.34
Heart failure is the common end-pathway of many structural and func-
tional cardiac diseases, which impair the ability of the ventricle(s) to fill
and/or eject the blood. It is a clinical syndrome characterized by typical
symptoms (e.g. breathlessness, ankle swelling, and fatigue) that may be
accompanied by signs (e.g. elevated jugular venous pressure, pulmonary
crackles, and peripheral oedema) caused by a structural and/or func-
tional cardiac abnormality.1
Comprehensive HF care is the integration of PC with guideline-directed
HF management applied concurrently, with the focus varying according
to needs, which change across time. It should be available to affected
people and their caregivers throughout the whole course of patient’s HF
journey.35 (Figure 1).
Advance care planning (ACP) is a process that enables individuals to de-
fine goals and preferences for future medical treatment and care, to dis-
cuss these goals and preferences with family and healthcare providers,
and to record and review these preferences if appropriate,36 for the case
of the loss of decision-making capacity.
3. Symptom assessment
The symptoms suffered by people with HF can be caused by HF itself
[e.g. breathlessness, fatigue, and weakness (Figure 2)], comorbidities (e.g.
musculoskeletal pain) and patients’ general condition or treatment side
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..effects (e.g. deconditioning, nausea, constipation, depression, anxiety,
sleep problems, confusion, and delirium).25,37,38 Symptoms that persist
despite optimal guideline-directed cardiologic treatment should trigger a
PC approach or involvement.39 These symptoms should be treated with
as much attention as improving heart function and prolonging survival.
This is particularly pertinent in advanced disease, including those awaiting
transplantation or ventricular assist device (VAD) implantation.40–42
Several symptoms that cause substantial suffering (e.g. depression, fa-
tigue, tiredness, and poor appetite) may be regarded as unimportant
given the seriousness of HF and, as a result, may be unaddressed. To en-
sure that patient-relevant causes of distress are identified and addressed,
symptoms should be assessed systematically.43 Extending the usual his-
tory by validated assessment tools increases the identification of symp-
toms 10-fold.44 Any symptom can be assessed using the Numeric Rating
Scale (NRS). Multi-symptom [the Edmonton Symptom Assessment
Scale (ESAS)],6,43,45,46 or multidimensional [the Integrated Palliative care
Outcome Scale (IPOS)47] tools can be used to assess symptoms com-
prehensively. Repeating the assessments helps quantify changes in symp-
tom burden and the effectiveness of treatment. The simplicity and
widespread distribution of the ESAS favours its broader use in clinical
practice. The burden caused by a given symptom depends on its inten-
sity, impact on functional capacity, and on QoL. For breathlessness, un-
pleasantness (reflecting affective distress it causes) should be assessed
additionally to its intensity.48 Anxiety and depression can be assessed us-
ing the Hospital Anxiety and Depression Scale (HADS).1,49–51 Disease
specific tools like the Kansas City Cardio-myopathy Questionnaire
(KCCQ) (for which there is a short-form of 12 questions) or PC-specific
like Functional Assessment of Chronic Illness Therapy–Palliative Care
scale (FACIT–Pal), can be used to evaluate factors that limit wellbeing
and monitor the efficacy of management.15,45
4. Triggers for initiating PC
provision
HF guidelines reinforce the focus on PC as an option for patients
with advanced/end-stage HF, or those who are at the EoL, indicating
however that ideally, PC should be introduced early in the disease
trajectory and increased as the disease progresses,1,8 so a needs and
symptoms assessment-based approach is a more suitable model
for integration of PC into cardiac care, than recognizing EoL.52
Reliance on prognostication as a trigger for the consideration of PC is
ineffective due to the poor utility of current prognostic tools53 and
because PC needs do not correlate with prognosis.54 Prognostic un-
certainty should trigger rather than block assessing of PC needs.55 As
discussed above, symptom assessment tools may be helpful in this
regard.56
Conversations about the goals of care, assessment of PC needs and
considerations of the need to include PC in the ongoing care can be initi-
ated at annual HF review visits in less advanced stages of HF, or after
each significant health-related events in more advanced stages58
(Figure 3). Triggers for a PC approach or consultation should include dis-
tressing symptoms, existential distress, recurrent HF exacerbation, and
progressive frailty or caregiver concerns.
Figure 1 The clinical course of heart failure with associated types and intensities of available therapies (modified from reference 57 with further
modification from reference 58). Reprinted with permission of the American Thoracic Society. CopyrightVC 2019 American Thoracic Society.
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.PC integration should start when the symptoms and problems begin
to emerge and persist and be provided alongside disease modifying
treatments. A needs assessment tool validated for people with HF:
the Needs Assessment Tool: Progressive Disease-HF (NAT: PD-HF)
can help to identify people who can benefit from PC.60 This tool
includes four major sections: the patient’s wellbeing; the caregiver’s
ability to provide care; the caregiver’s wellbeing; and issues that should
raise consideration of referral to specialist services such as the lack of
a caregiver.56 Each section has a series of prompts, which act as an
aide to assess the level of concern about unmet needs (none, some,
significant) and identify the action taken by the clinician (managed by the
clinician, managed within the team, referral to other resources). People
with HF are deemed to have important needs if they were assessed as
having ‘significant concern’ on any of the NAT:PD-HF patient wellbeing
domains.32 This assessment tool is designed to be completed in less than
a minute at the end of a consultation and, in cancer patients, has been
shown to reduce the level of unmet needs without prolonging consulta-
tions. It has recently been translated and validated in Dutch, and transla-
tions into other languages are in progress.61 Supportive and PC
Indicators Tool (SPICT) can help to identify people who may have PC
needs based on the risk of deterioration and dying, although it neither
identifies what those needs are nor triages corresponding action.62 A
combination of tools allows for a variety of triggers to flag the need for
re-negotiating goals of care.
Basic PC related definitions and key principles of PC relevant for care
for people with HF are summarized in Table 1.
Figure 2 The pathophysiology of main heart failure symptoms, related to palliative care. (Most relevant symptoms marked with bold upper case.)
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Figure 3 Palliative care provision for people with heart failure—flow chart.
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..5. Symptom management
5.1 Breathlessness
Breathlessness (dyspnoea) is the subjective experience of breathing
discomfort or difficulty in breathing that consists of qualitatively dis-
tinct sensations that vary in intensity.48 It can be acute, chronic, or epi-
sodic with the episodes usually superimposing on chronic (constantly
present with usual fluctuations) difficulties in breathing. Episodic
breathlessness is a severe worsening of breathlessness intensity or un-
pleasantness, beyond the usual fluctuations in the patient’s percep-
tion.63–65 Breathlessness that persists despite optimal treatment of
the underlying pathophysiology and results in disability is defined as a
chronic breathlessness syndrome, which requires symptomatic man-
agement.66,67 Breathlessness is reported by almost 90% of people
experiencing advanced HF and is usually present at minimal exertion
or at rest, substantially limiting the patients’ QoL and daily activities
such as bathing or dressing.68 Chronic breathlessness in people with
HF can be related to haemodynamic status, skeletal myopathy and sar-
copenia, chronic or acute comorbidities.16,69 In the case of breathless-
ness exacerbation, potentially reversible aggravating factors should be
sought and if appropriate, specifically treated. After or parallel to opti-
mizing the guidelines recommended treatment of HF (re-establishing
and/or maintaining optimal volume status)1,9,12,14 and/or concomitant
disease, non-pharmacological and pharmacological symptomatic
treatment should be pursued. Most studies on symptomatic/palliative
breathlessness management have been performed on unselected
cohorts, so conclusions with respect to efficacy and safety specific in a
HF population should be drawn with caution. Appropriately tailored
exercise helps to improve functional capacity and skeletal myopathy.
A physiotherapeutic approach, including breathing training, neuro-
electrical leg muscle stimulation, or use of a hand-fan and walking-aids
are considered as potentially helpful. Relaxation, breathing-relaxation
training, and psychological interventions can be tried.70 Oxygen ther-
apy can ameliorate breathlessness in hypoxemic patients, but the data
do not support use in those who are only mildly hypoxemic or nor-
moxaemic.71 Pharmacological symptomatic treatment of breathless-
ness is based on opioids. The evidence for their efficacy is strongest
for people with stable chronic obstructive pulmonary disease
(COPD).72 The beneficial effect of opioids on breathlessness probably
does not depend on its aetiology,73 but data on the short-term use of
opioids in people with HF are conflicting and data for longer-term use
are promising, but inconclusive.74–76
Most studies on symptomatic breathlessness management have been
performed using oral low-dose morphine. Oral low-dose sustained re-
lease morphine has recently had its licensed indication extended to
chronic breathlessness due to COPD, HF or cancer by the Therapeutic
..............................................................................................................................................................................................................................
Table 1 Principles of palliative care for people living with heart failure
Topic Description Clinical implications for care of people with heart failure
Palliative care Active care often provided alongside disease modifying
management; it should be introduced early in the dis-
ease trajectory and increased as the disease progress,
on the basis of patient’s and caregivers’ needs.
Palliative care supplements optimal cardiologic treatment strategies by in-
troducing interventions focused on addressing physical symptoms, psy-
chosocial, and spiritual problems.
Hospice care A specific form of PC service, providing care for people
approaching death and those who love them
People with advanced heart failure, for whom further hospitalizations are
no longer appropriate/not wanted, can receive appropriate care pro-
vided by specialist PC team in home like institutions.
End-of-life Period of from several months until the last few days of
life, characterized by continuous disease progression
despite optimal cardiologic treatment.
Process of treatment goals adjusting, focusing more on care than curing.
Stepwise preparedness for dying could be appropriate for some people
with as their heart failure worsens.
Symptoms and prob-
lems assessment
Using validated symptoms/problems assessment tools:
-increases the detectability of symptoms/problems,
-allows evaluation effectiveness of treatment/interven-
tions focused to alleviate them.
Multi-symptom ESAS (free available in over 30 languages59), multidimen-
sional IPOS (evaluating physical symptoms, psychological and social
problems), HADS, and PHQ-9 are validated tools that can be used to
assess symptoms and problems in people with heart failure.
Triggers for initiating
palliative care
Recognition of persisting symptoms or existence of
unaddressed PC needs helps to recognize need for in-
tensification of PC involvement.
Persistence of ongoing troublesome symptoms/problems despite optimal
HF therapy should imply to start/intensify PC provision (as approach,
involvement of specialist PC or referral). Tools assessing symptoms/
problems (like ESAS, IPOS, HADS, PH-9) or comprehensive palliative
care needs assessment tools (like NAT: PD-HF) can help to identify
those with unmet needs, including caregivers.
Palliative Care
services
PC may be delivered in any clinical care setting including
inpatient and outpatient units and at the patient’s
own home: it encompasses a palliative approach, spe-
cialist PC consultation or involvement of specialist PC
multi-disciplinary team.
Collaboration between cardiology and PC is pivotal to ensuring access to
PC to all people living with HF throughout the whole course of disease,
irrespective of their current place of care, accordingly to their needs.
In the absence of any agreed service model, the cardiac team should at
least have access to a PC specialist and vice versa as part of their extended
teams.
ESAS, Edmonton Symptom Assessment System; HADS, Hospital Anxiety and Depression Scale; IPOS, Integrated Palliative care Outcome Scale; NAD: PD-HF, Assessment Tool:
Progressive Disease-Heart Failure; PHQ-9, brief Patient Health Questionnaire.
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Goods Administration of Australia. Therefore this is the only drug and
drug preparation anywhere in the world with a license for use in chronic
breathlessness. Although the studies of morphine in HF give conflicting
findings, based on the licensed dosing schedule morphine should be
started at 10 mg per day, given to provide a steady state according to
preparation (2.5 mg immediate release regularly four times daily; 5 mg
modified release twice daily or 10 mg modified release once daily). In a
dose increment study of people with a range of causes of breathlessness,
a clinically important improvement occurred in 63% participants, 67% of
responders benefited by 10 mg per day, 25% and 8% required dose esca-
lation to 20 mg or 30 mg of morphine per day respectively.77,78 After the
start of treatment or dose increment, the initial response, if present, is
seen in the first 24 h, however the magnitude of improvement may grow
during a week (up to doubling the effect). If the response is inadequate,
dose increases should not occur for at least one week. Doses can be ti-
trated to a maximum of 30 mg/24 h of oral morphine (or equivalent
dose of other opioid) if appropriate; a dose which appears to be unre-
lated to excess mortality or hospital admission, at least in people with se-
vere COPD.79 In significant renal impairment (Stages 4 and 5 of chronic
kidney disease i.e. GFR <30 mL/min), something quite common among
people with advanced HF and older adults, morphine should be avoided,
used with caution, and/or switched to another opioid not having active
metabolites with renal excretion.80 Other opioids are sometimes used
for breathlessness management, but there are no published adequately
powered, placebo-controlled data in people with HF for this indication
for any, other than oxycodone, where there was no benefit over pla-
cebo.74 Phase 2 studies with fentanyl show promise.81 It is unknown if
the alleviation of breathlessness is a specific feature of morphine or a
class effect.
The most recent Cochrane review of benzodiazepines demonstrated
a lack of evidence either for or against benzodiazepines. None of the
published studies were done in people with HF. As the use of benzodia-
zepines has been associated with increased risk of all-cause mortality in
severe COPD and other morbidity such as falls, caution is advised.
Benzodiazepines, if at all, should be used as second- or third-line therapy,
in acute episodes when other measures have failed and anxiety signifi-
cantly aggravates distress.79,82–85
5.2 Pain
Pain is present in most patients with advanced HF. The prevalence of
pain increases with age and functional class, reaching 89% in those with
NYHA Class IV HF.86–88 At least moderate pain is reported by 61% of
hospitalized HF patients, and pain at more than one site by 40%.6,89
Chronic pain, if inadequately treated (which occurs more frequently for
people with HF than for those with cancer90), degrades QoL87,91 and
correlates with fatigue and depression.92 Untreated pain is also associ-
ated with more frequent hospital admissions due to HF-decompensa-
tion.93 The involvement of PC services improves the burden of pain in
in- and out-HF-patients.26,89 Pain can be of cardiac (ischaemic) or non-
cardiac (musculoskeletal, or caused by dyspepsia, gout, peripheral vascu-
lar disease, oedematous legs, or tense ascites) origin.94–97 Appropriate
management should be based on the likely pathophysiological mecha-
nism of the pain, such as neuropathic, ischaemic, nociceptive, or inflam-
matory (for review see reference 98). Cardiac ischaemic pain is usually
controlled with anti-anginal medication, but there are patients for whom
this remains a severe problem despite optimal cardiologic treatment.
Spinal cord stimulation might be considered in chronic refractory an-
gina.99–102 Intravenous strong opioids, such as morphine, are recom-
mended for the relief of severe anginal pain related to acute coronary
syndromes.103 Opioids slow gastric emptying and might delay the ab-
sorption of orally administered antiplatelet agents. Administration of
crushed tablets, prokinetic drugs, or parenteral loading are proposed to
overcome this undesirable effect.104–106
For chronic non-cancer pain, non-pharmacologic and non-opioid
pharmacologic therapy are preferred.107 Non-steroidal anti-inflamma-
tory (NSAIDs) drugs increase fluid retention and should be avoided in
patients with HF. Previously stable patients started on a NSAID have an
increased risk of worsening HF.108 Many people with HF also have renal
dysfunction and take a loop diuretic and ACE inhibitor—adding NSAID
increases renal strain, particularly in the older adult. Paracetamol appears
to be safe in HF.109 Topical NSAIDs might be tried; however, their safety
has not been studied in HF patients. Data regarding the long-term use of
strong opioids in chronic non-cancer pain are mixed overall and very lim-
ited in people with HF, and the risk of side effects and addiction should
be carefully balanced in the decision to prescribe them. The opioids, if
appropriate should be considered if pain persists despite non-
pharmacological and non-opioid pharmacologic therapy and in the low-
est dose for the shortest duration. In people with severely impaired renal
function opioids with a safer metabolic profile, such as methadone,
buprenorphine, or fentanyl, are preferred.
5.3 Depression and anxiety
The prevalence of depression among people with HF, especially in its ad-
vanced stage, is significantly higher than in the general population (up to
42% and 70% respectively vs. 20%).49,110 Depression is an important,
modifiable risk factor of HF-related hospitalization and death, and inde-
pendent negative prognostic indicator. It also contributes to overall
poor QoL.1,49,110–112 The co-existence of depression results in poor
self-care, decreased medication adherence, increased smoking, and de-
creased activity leading to deconditioning and weight gain.49 In contrast,
anxiety often considered in connection with depression, does not seem
more prevalent in HF than in the general population and does not pose
the same risks as depression.49,110,111,113,114 Anxiety is associated with
poor physical functioning due to the inability of individuals to implement
effective coping strategies.115
Depressive symptoms may overlap with HF symptoms, making the di-
agnosis of depression more complicated.116 A vicious cycle ensues be-
tween depression and HF. Depression causes the activation of the
hypothalamus-pituitary-adrenal (HPA) axis, resulting in elevation of cor-
tisol level.49 Due to the association of depression with reduced func-
tional performance and HF instability, it is recommended that all HF
patients be assessed for depression and treated if appropri-
ate.92,114,117,118 To date, there are no published guidelines on the treat-
ment of depression for people with HF but a number of approaches
have demonstrated the improvement of depressive symptoms, physical
function, QoL, and self-management skills, but not overall outcome. An
integrated approach from a multidisciplinary team is recommended.
Cognitive behavioural therapy and aerobic exercise training seem to give
promising results. Pharmacological interventions may be necessary for
some patients to treat depression but also to inhibit excessive activation
of the neuroendocrine HPA axis related to the depression.49 The selec-
tion of efficient and safe antidepressants, however, is challenging.
Selective serotonin uptake inhibitors (SSRI) and alfa2-antagonists (mirta-
zapine) are thought to be the safest group of antidepressants for patients
with HF, but the evidence is limited.1 However, similarly to Monoamine
Oxidase Inhibitors (MAOIs), they can cause hypertension.49 Tricyclic
antidepressants (TCA) can provoke orthostatic hypotension, worsening
of HF and arrhythmias, and should be avoided in HF.1,49 TCA and several
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.SSRI (like citalopram) and mirtazapine can cause the prolongation of QT
interval predisposing the development of ventricular tachycardia.49
Elements of PC management most relevant in care for people with HF
are summarized in Table 2.
6. Advance care planning
ACP is an essential component of PC, it increases the completion of ad-
vance directives, discussion of EoL preferences, improves the concor-
dance between preferred and received care and might decrease
rehospitalizations at the EoL.119,120 Yet, ACP is often not done or poorly
conducted in patients with HF. Preferences for life-sustaining treatments
are often not discussed and documented resuscitation orders may differ
from patient preferences.121,122 Clinicians caring for patients with HF re-
port as important barriers to ACP: reluctance of patients or family mem-
bers to accept a poor prognosis, difficulty of patients or family members
to understand limitations or adverse effects of life-sustaining treatments,
and discordance among family members about the goals of care.123
Patients and family members report as important barriers to ACP: un-
certainty about care they would desire, a preference to concentrate on
staying alive than talking about EoL care and uncertainty about which
doctor is responsible for EoL care.124 Overcoming these barriers is im-
portant for the delivery of high-quality PC. In fact, ACP leads to open
communication and may give patients feelings of relief and more control
about their care.125 ACP can be initiated at any stage of a person’s life.36
HF has an unpredictable trajectory. Moreover it increases the risk of cog-
nitive impairment.126,127 Therefore, timely ACP, when the patient is able
to participate in decision-making process should be a standard element
of clinical care of people with HF and ACP should not be postponed until
a patient approaches the end stage of his or her disease.39 Nevertheless,
identifying the appropriate moment in the course of the disease trajec-
tory to start ACP can facilitate the process.128
ACP should be considered at transition points during the course of
the disease like hospital admission, symptom burden or functional de-
cline despite optimal disease specific treatment, and the exhaustion of
disease-oriented treatment options.128 ACP should to be adapted to the
patient’s readiness to engage in ACP and should not be limited to discus-
sing and recording life-sustaining treatment preferences.36 Indeed,
communication about the goals of care and addressing the concerns of
the patient and loved ones about the EoL are paramount.
Communication with PC consultants or teams can help to identify or re-
focus goals of care.53,129,130 Furthermore, previously documented goals
of care and preferences regarding (life-sustaining) treatments and care
should be updated regularly.131,132 Disease-specific aspects need to be
addressed where appropriate, such as fear of dyspnoea at the EoL,
reprogramming of an implantable cardioverter-defibrillator (ICD), so
that it does not deliver shocks or withdrawing mechanical circulatory
support delivered by VADs in the dying phase.133
7. Whole person care and
spirituality
The ‘Whole Person Care’ concept is based on treating the patient as an
integral human being consisting of an inseparable body, mind, and spirit.
Providing the very best medical service adjusted by psychological and
spiritual care ensures that the person is addressed as an integral individ-
ual, even if optimally fixed medical issues cannot cure the disease.
Addressing medical, psychological, and spiritual needs facilitates the pro-
cess of growing personal integrity in response to even incurable disease
or injury. This growth of the sense of integrity or wholeness is known as
the process of healing. This concept recognizes the meaning of relations
between all those participating/involved in the care for a person: a pa-
tient her- or himself, her or his family, friends and caring team,134,135 and
reinforces the role of spirituality in a person’s life in addition to physical
and mental dimensions.
Spirituality has a multidimensional nature, and encompasses existential
questions, values, and religious matters.136 Although spirituality is recog-
nized as one of the four dimensions in PC, research in this area is under-
developed in terms of people with HF. Studies have shown that
spirituality is an important and integral component of QoL and affects
the person’s ability to place their difficulties in perspective.137 The spiri-
tual needs of people with HF and their carers are influenced by hopeless-
ness, isolation and altered self-image (loss of confidence, dependency,
being a burden) associated with chronic illness and disability.138 In ad-
vanced HF, spiritual wellbeing remains stable over time and varies
..............................................................................................................................................................................................................................
Table 2 Elements of palliative care management most relevant in care for people with heart failure
Topic Description Clinical implications for care people with heart failure
Breathlessness—
palliative
management
Breathlessness (at rest or at slight exertion)
persisting despite continuously optimized
cardiologic treatment should be recog-
nized as indication for symptomatic
management.
Multi-modal PC management including breathing-relaxation training, cognitive-
behavioural therapy, walking aids, hand-held fans, and low-dose oral morphine
may improve breathlessness intensity, unpleasantness and/or its impact of the
functional capacity.
Pain management Pain is a common symptom among people
with HF, often being caused by concomi-
tant disease and requires symptomatic
management.
Local and non-pharmacological therapies should be applied if applicable. Opioids
should be considered for pharmacologic pain management in people with heart
failure, taking into account renal function.
Systemic non-steroid anti-inflammatory drugs are contraindicated. Paracetamol is
considered as free of undesirable cardiovascular side effects.
Depression
management
Depression as common comorbidity, in-
creasing risk of rehospitalization, and limit-
ing the QoL
Depression should be actively sought. The management should be based on
multi-modal interventions (including cognitive behavioural therapy) with the
pharmacotherapy based on selected SSRI or mirtazapine, as second line
intervention.
8 P.Z. Sobanski et al.
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according to race and symptom distress.139 Social and psychological de-
cline both tend to track the physical decline, while spiritual distress fluc-
tuates independently.140 Experiencing spiritual peace better predicts
mortality than functional status and comorbidity141 and greater spiritual
well-being is associated with a lower incidence of depression.142 Hope
and hopelessness are constructs conceptually linked with depression
and spirituality. One study indicates that expression of hope positively
affects cardiovascular outcomes.143 Adjunct spiritual counselling appears
to have a positive impact on QoL.144
Besides the openness to the spiritual dimension of the patient, the
whole person care approach focuses the clinician additionally on curing
the illness, acknowledging the simultaneous process of internal healing,
i.e., ‘becoming psychologically and spiritually more integrated and whole;
a phenomenon which enables persons to become more completely
themselves and more fully alive’.145 As the relationship between clinician
and the patient has a mandatory meaning for healing, medical professio-
nals should be therapeutically present (be on hand i.e. ‘here and now’);
enhance the patient’s dignity and his or her sense of being a unique hu-
man being; be open to the spiritual needs of the patient and cooperate
with specialists in spiritual care such as chaplains; be ready to assist in the
patient’s quest for meaning; and take care of her- or himself (including
self-development, as a person and as a professional).
Spiritual care, which addresses an essential aspect of humanity, should
be integrated into care for people with HF within a wide range of inter-
ventions and attitudes (from the therapeutic presence of clinicians to the
professional help offered by specialists in spiritual care/chaplains, pastoral
care workers).146
8. Addressing ethical dilemmas
Four ethical principles encompass dilemmas that arise during the care of
people with advanced HF: beneficence, non-maleficence, respect for pa-
tient autonomy, and justice.147
Beneficence refers to the clinician’s duty to act for the good or benefit of
patients. Non-maleficence refers to the clinician’s duty to prevent or avoid
harming patients. Clinicians should weigh the anticipated benefits and harms
of tests and treatments in the context of the patient’s prognosis and health
care-related goals. ‘Double effect’ is a well-established concept that allows
clinicians to prescribe potentially harmful medications, procedures, or other
treatments if the intent is good, the harmful effect is not intended, and the
potential benefit of the treatment outweigh the harms.148,149
Respect for patient autonomy requires that clinicians inform patients
about their diseases and prognoses and the risks, benefits and alterna-
tives to tests and treatments. Regarding patients with advanced HF, clini-
cians should inform those with implantable cardiac devices (e.g. ICDs) of
the option of withdrawing device therapies or ‘device’s function deacti-
vation’ (e.g. reprogramming an ICD so that it does not deliver
shocks).150,151 Clinicians should ensure patients’ decisions to refuse or
request the withdrawal of therapies are informed and respect such deci-
sions.151 Respect for patient autonomy also underlies the process of
ACP; clinicians should encourage patients with advanced HF to articulate
and document their health care-related values, goals, and preferences.149
Justice requires that clinicians base their testing and treatment recom-
mendations on medical evidence and need, not on patient-specific char-
acteristics (e.g. race and sex).152
Ethical dilemmas that arise when caring for patients, occur when two
or more of the aforementioned ethical principles conflict with each
other. In patients with advanced HF decision making regarding
withholding or withdrawing life-sustaining treatments commonly precipi-
tates these dilemmas. For example, if a patient’s request for deactivation
of an implantable cardiac device (i.e. withdrawal of device therapies) con-
flicts with the clinician’s perceived beneficence and non-maleficence
duties, the clinician should strive to resolve the dilemma (e.g. care con-
ference). For situations in which such dilemmas cannot be resolved,
ethics consultation and/or PC consultation should be considered. There
are multiple approaches to ethics consultation.149 However, most in-
volve systematically reviewing the patient’s medical situation and health
care-related values, goals and preferences, QoL concerns, contextual
features associated with specific case, and other factors. This approach
usually defines the ethical dilemma and suggests a solution to resolve it.
9. Adjustment of medical therapy
Transition of the goals of care towards improving comfort and focusing
on alleviating symptoms requires compassionate communication with
patients and their families and loved ones and should be connected with a
review of ongoing therapies with respect to their applicability. The validity
of former indications for their use, after setting new goals, should be evalu-
ated. Continuous optimization of HF therapy should be pursued, if only
possible.1,9,14 Treatments relevant for symptom management or preven-
tion should be continued if well tolerated and the dose regularly reviewed.
Medicines prescribed for indications that are becoming no longer relevant
should be considered for withdrawal. Therapies causing undesirable side
effects and preventive drugs, especially those with a long delay in showing
their benefits, such as statins, should be stopped.153 However, routinely
stopping any HF treatment when starting PC is inappropriate as many HF
treatments, like angiotensin-converting enzyme inhibitors (ACEI) and an-
giotensin II type I receptor blockers (ARB) or angiotensin receptor-
neprilysin inhibitors (ARNIs) as they may be important for symptom con-
trol.1 Diuretics help maintain euvolaemia and control breathlessness and
should not be withdrawn unless there is a clear reason to do so.154 If the
patient’s condition deteriorates and fluid intake decreases, diuretic dose
reduction could be appropriate. ACEI, ARB, or ARNI may help prevent
pulmonary congestion but can cause symptomatic hypotension or the
worsening of renal function. Dose reduction or discontinuation should be
individually tailored.155 Beta-blockers prevent tachycardia and/or angina,
especially in patients with atrial fibrillation (and) prone to rapid ventricular
rate. If they need to be reduced or stopped due to symptomatic hypoten-
sion or low cardiac output, this should be done gradually and digoxin may
become an alternative.155 In the case of significant bradycardia, beta-
blockers should be reduced or stopped. Inotropic drugs may provide
symptomatic benefits in advanced HF as part of a PC approach.1,14,156 The
intermittent infusion of intravenous inotropes might sometimes be consid-
ered as PC intervention in inpatient institutions or even in home care to
improve both symptoms and QoL.157–161 Inotropic drugs should not be
started or continued in patients who are actively dying as they usually no
longer provide any symptomatic benefits in such situations.162 If HF status
improves, re-adjustment of therapy is then needed, including both restart-
ing or increasing previously reduced doses of HF medication, and/or re-
ducing or withdrawing PC medications (e.g. opioids after breathlessness
or pain has improved).
In patients with an active ICD, the option of reprogramming the de-
vice at the EoL, to avoid potentially painful and usually futile shocks
should be discussed in advance and, if agreed, performed timely.163,164
Anti-tachycardia pacing (ATP), which is generally well tolerated can be left
active if the patient does not wish to deactivate all anti-tachyarrhythmic
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therapies or if it might be in the patient’s best interests. More complex are
requests for pacemaker deactivation. Some patients fear that an active
pacemaker can prolong dying. However, this therapy neither prolongs dy-
ing nor causes symptoms, furthermore anti-bradycardia pacing can im-
prove QoL, even in patients who are dying, by preventing symptoms
caused by low heart rate and/or pauses in heart rhythm (e.g. dizziness, pre-
syncope, and breathlessness).165–167 Likewise, discontinuing the resynch-
ronization component should be avoided, as the loss of pacemaker-
mediated synchronization can precipitate HF-related symptoms.151,168 A
multidisciplinary approach should be considered including PC and cardiol-
ogy, and ethics if needed, when patients or their caregivers request deacti-
vation of antibradycardia or resynchronization pacing.
10. Care for dying
About 60–70% of deaths in patients with HF have a cardiovascular cause,
with HF-related death being either sudden or caused by progressive
pump failure.169–171 For this reason, a team caring for people with HF
should be familiar with diagnosing dying, caring for the dying, looking af-
ter the bereaved, and communicating about these issues. Diagnosing dy-
ing should be based on a multidisciplinary team discussion, in order to
align the clinical perceptions of different professions.172,173 During the
dying phase, progressive weakness and immobilization, loss of interest in
eating and drinking, cognitive impairment with diminishing verbal com-
munication, changes in breathing pattern, and existential suffering might
occur.174–176 Dying is a dynamic process characterized by changes in di-
agnostic appraisal, as well as physical, psychosocial, and/or spiritual needs
of the patient and their family and loved ones.
Many people prefer to die at home, but 60–80% of all patients will die
in institutions like hospitals, nursing homes, residential homes, and hospi-
ces.177–179 The preference with respect to place of care whilst dying can
change during the course of the disease.180,181 The presence of a family
caregiver who supports a patient’s wish to die at home is one of the most
important factors enabling a home death.177,182–184 Therefore, counsel-
ling, support, reassurance, and encouragement of relatives should be a
major component of psychosocial care for patients and their families.185
Earlier ACP contributes to realizing patient preferences.186–190
When dying occurs, moist breathing (a ‘death rattle’) and confusion
are common.191 If for any reason ICD has not been deactivated previ-
ously, and unwanted ICD shocks occur, a magnet can be taped over the
device generator to prevent further shocks and perform electronic deac-
tivation if possible.150,151,192–195
All diagnostic, therapeutic, and nursing interventions that do not con-
tribute to the aim of preserving the highest level of comfort should be
discontinued or not initiated.185,196
Palliative Care interventions most relevant in supporting people living
with HF are summarized in Table 3.
..............................................................................................................................................................................................................................
Table 3 Palliative care interventions relevant in supporting people with heart failure
Topic Description Clinical implications for care people with heart failure
Advance care plan-
ning (ACP)
Process of compassionate communication on disease
progression, helping individuals to define goals of care
and preferences for future medical treatment and
care, especially life-sustaining treatments. The
conclusions of the ACP can be: the recording of
advance directives or the indication of a personal
representative for medical decision-making.
Disease-specific aspects need to be addressed as part of ACP, such as fear
of breathlessness or uncontrolled pain at the end of life or management
of an implantable cardioverter-defibrillator in the dying phase.
Addressing ethical
dilemmas
Four ethical principles guide decision making that arise
during the care of patients with advanced HF: benefi-
cence, non-maleficence, respect for patient autonomy,
and justice.
Ethical dilemmas that arise when caring for patients usu-
ally occur when two or more ethical principles are in
conflict with one another.
Respect for patient autonomy requires that clinicians inform people with
advanced HF about their disease, prognosis and the risks, benefits and
alternatives to tests and treatments including, in those with implantable
cardiac devices, the option of withdrawing device therapies or ‘device deac-
tivation’. Respect for patient autonomy also underlies the process of ACP.
For situations in which such dilemmas cannot be resolved, ethics consulta-
tion and/or PC consultation should be considered.
Spiritual care Address religious needs, values, and the existential
quest.
Spiritual care involves a wide range of interventions from the therapeutic
presence of clinicians to the professional help offered by specialists in
spiritual care/chaplains and pastoral care workers.
Adjusting medical
therapy
The validity of former indications for drugs use, after
setting new goals, should be continually evaluated.
Adjustment of medical therapy is a dynamic process that might include re-
ducing doses/withdrawing of ongoing medication if it is no longer benef-
icent especially if causing unpleasant side effects or restarting/up-
titrating previously withdrawn/reduced doses of drugs after improve-
ment of clinical situation. The rule is: harm, burden or long-term effect
= stop; symptom improvement = continue/adjust dose.
Care for the dying Dying is a medical diagnosis and diagnosing it should be
neither neglected nor postponed.
Dying is a dynamic process, with changing symptoms
and signs, requires if complex intensive palliative care.
Patients and their families should receive appropriate counselling, support,
and reassurance. All interventions and therapies that do not contribute
to the aim of preserving the highest level of comfort should be discon-
tinued or not initiated. This also includes the deactivation of ICDs and
other devices (if not performed previously).
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11. PC services
An interdisciplinary approach encompasses the patient, her or his family,
and loved ones and addresses PC needs wherever the patient is—at
home or in institution. PC is divided into generic and specialist PC.18,31
Generic PC, termed the ‘PC approach’, is provided by all health profes-
sionals, who have basic PC training and incorporate PC principles into
routine patient care. Specialist PC is provided by a multi-professional
team for whom PC is the core practice and who has specialist training in
PC. Specialist PC is needed for patients with needs or problems that are
complex and/or persist despite generic PC.197 PC should be provided
alongside optimal disease specific management and care.1,8,32
The complex nature of the needs and symptoms experienced by peo-
ple with HF require multi-disciplinary collaboration between cardiology
and PC.1,198 Both HF and palliative management need to be regularly
reviewed and optimized. Most PC concerns should be within the skills of
the usual care teams (cardiology, primary care, care of older adults), sup-
ported by a specialist PC for education, training, and clinical care if
needed. For this reason, it could be reasonable to have a PC team, or at
least a PC specialist in the cardiac team, and a cardiologist in the PC
team. The PC team usually encompasses physicians, nurses, allied health
professionals (AHPs), and chaplains, sometimes being supported by
pharmacists and ethicists. The term AHP includes psychologists, pharma-
cists, physiotherapists, dietitians, speech and language therapists, occupa-
tional therapists, and social workers. Each discipline/profession plays a
role in addressing patients’ and relatives’ PC needs. AHPs provide a reha-
bilitative approach, energy conservation techniques, enablement, self-
management, and self-care.199 Physiotherapy and occupational therapy-
led interventions are especially important for non-pharmacological
breathlessness management199–201 and the improvement of functional
ability.202–204 Occupational therapists have core skills in non-
pharmacological fatigue and anxiety management, along with the assess-
ment and provision of equipment to maintain function and optimize
QoL.205 PC provides as well bereavement service to support these who
lost a loved one.
Despite the promising evidence supporting the involvement of multi-
disciplinary PC in the care of people with HF,15,26,28,29 there have been
no trials to test which model of service provision is the most effective, al-
though the use of an integrated approach based on the identification and
triage of problems is promising55 Services may be led by cardiologists,
PC specialists, or jointly, and include common core components of
care.206–211
12. Conclusions
PC improves the QoL of many people living with HF, their families and
loved ones. For most, generic PC along with optimal HF care is all that is
required and can be provided by the core team (cardiology, primary
care, or care of older adults) with access to specialist PC as needed. The
most important step in the improvement of PC provision for people
with HF is the proper understanding of a broad spectrum of PC services
and the recognition of the PC needs they have. Symptom management,
support in decision-making, communication including disease progres-
sion and EoL issues, advance care planning as well as addressing psycho-
social and spiritual problems are the fields PC is focused on. PC should
complement cardiologic care, and not be seen as an alternative to it.
A responsive integrated cardiac and PC for all patients with HF when
needed regardless of prognosis should be the landmark of modern com-
prehensive care for people with heart disease.
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